Zhigang Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhigang Wu has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Peng George Wang
Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China
12 shared publications - Wanyi Guan
Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Key Laboratory of Molecular and Cellular Biology, College of Life Sciences, Hebei Normal University, Shijiazhuang, Hebei 050024, China
9 shared publications Cheng Ma
Department of Chemistry and Center of Diagnostics & Therapeutics, Georgia State University, Atlanta, GA 30303, USA.
6 shared publications- Hailiang Zhu
Department of BioMolecular Sciences, University of Mississippi, Oxford, Mississippi 38655, United States
5 shared publications - He Zhu
Department of Chemistry and Center for Therapeutics and Diagnostics , Georgia State University , Atlanta , Georgia 30302 , United States
4 shared publications Lei Li
Department of Chemistry and Center of Diagnostics & Therapeutics, Georgia State University, Atlanta, GA 30303, USA.
4 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Elsevier in SSRN Electronic Journal
Gram-Scale Enzymatic Synthesis of Lacto-N-fucopentaose-I, -II, and -III and Their Protective Effects Against Necrotizing Enterocolitis in Neonatal Mice
Human milk oligosaccharides (HMOs) are implicated in protection against necrotizing enterocolitis (NEC), yet evaluating their structure-activity relationships is hindered by the limited availability of defined fucosylated isomers. Here, we achieved gram-scale enzymatic synthesis of three lacto-N-fucopentaose isomers (LNFP-I, -II, and -III), and administered them to neonatal mice with NEC at either physiological breast-milk concentrations or equimolar doses (normalized to 2'-FL) to distinguish structural effects from concentration effects. All three LNFP isomers attenuated NEC severity through coordinated actions on inflammation, barrier integrity, epithelial proliferation, apoptosis, and gut microbiome remodeling. Notably, LNFP-I, sharing the terminal α1-2 fucose epitope with 2'-FL, showed superior suppression of intestinal IL-1β and IL-6 compared with LNFP-III (p < 0.05), while LNFP-II exhibited more pronounced effects on gut microbiota, including increased alpha diversity and reduced Escherichia-Shigella abundance. Dose-dependent effects were observed primarily for apoptosis suppression, with only equimolar doses significantly reducing cleaved caspase-3 (p < 0.05). These findings reveal that complex fucosylated HMOs, specifically the pentasaccharide LNFP isomers, confer structure-dependent functional profiles against NEC, with LNFP-I excelling in anti-inflammation and LNFP-II prevailing in microbiota modulation. This work underscores that both structural selection and dosage optimization are critical for developing effective HMO-based NEC prevention strategies.
- 3 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessGram-Scale Enzymatic Synthesis of Lacto-N-fucopentaose-I, -II, and -III and Their Protective Effects Against Necrotizing Enterocolitis in Neonatal Mice
Human milk oligosaccharides (HMOs) are implicated in protection against necrotizing enterocolitis (NEC), yet evaluating their structure-activity relationships is hindered by the limited availability of defined fucosylated isomers. Here, we achieved gram-scale enzymatic synthesis of three lacto-N-fucopentaose isomers (LNFP-I, -II, and -III), and administered them to neonatal mice with NEC at either physiological breast-milk concentrations or equimolar doses (normalized to 2'-FL) to distinguish structural effects from concentration effects. All three LNFP isomers attenuated NEC severity through coordinated actions on inflammation, barrier integrity, epithelial proliferation, apoptosis, and gut microbiome remodeling. Notably, LNFP-I, sharing the terminal α1-2 fucose epitope with 2'-FL, showed superior suppression of intestinal IL-1β and IL-6 compared with LNFP-III (p < 0.05), while LNFP-II exhibited more pronounced effects on gut microbiota, including increased alpha diversity and reduced Escherichia-Shigella abundance. Dose-dependent effects were observed primarily for apoptosis suppression, with only equimolar doses significantly reducing cleaved caspase-3 (p < 0.05). These findings reveal that complex fucosylated HMOs, specifically the pentasaccharide LNFP isomers, confer structure-dependent functional profiles against NEC, with LNFP-I excelling in anti-inflammation and LNFP-II prevailing in microbiota modulation. This work underscores that both structural selection and dosage optimization are critical for developing effective HMO-based NEC prevention strategies.
- Open Access
- 3 November 2022
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 12 (49) , 31892-31899
Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation
In this study, an approach to prepare long-acting glucagon-like peptide 1 (GLP-1) by site-directed enzymatic glycosylation with homogeneous biantennary complex-type N-glycan has been developed. All the N-glycan-modified GLP-1 analogues preserved an unchanged secondary structure. The glycosylated GLP-1 analogues with sialyl complex-type N-glycan modified at Asn26 and Asn34 exhibited a 36.7- and 24.0-fold in vitro half-life respectively when incubated with dipeptidyl peptidase-IV (DPP-IV), and 25.0- and 13.9-fold respectively when incubated with mouse serum. Compared to native GLP-1, both glycosylated GLP-1 analogues modified at Asn34 by asialyl and sialyl N-glycan demonstrated lower maximum blood glucose levels, as well as more rapid and more persistent glucose-stabilizing capability in type 2 diabetic db/db mice. Our results indicated that the selection of an appropriate position (to avoid hindering the peptide-receptor binding) is crucial for N-glycan modification and its sialylation to improve the therapeutic properties of the modified peptides. The information learned would facilitate future design of therapeutic glycopeptides/glycoproteins with N-glycan to achieve enhanced pharmacological properties.
- 3 November 2022
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 12 (49) , 31892-31899
Open AccessIdentification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation
In this study, an approach to prepare long-acting glucagon-like peptide 1 (GLP-1) by site-directed enzymatic glycosylation with homogeneous biantennary complex-type N-glycan has been developed. All the N-glycan-modified GLP-1 analogues preserved an unchanged secondary structure. The glycosylated GLP-1 analogues with sialyl complex-type N-glycan modified at Asn26 and Asn34 exhibited a 36.7- and 24.0-fold in vitro half-life respectively when incubated with dipeptidyl peptidase-IV (DPP-IV), and 25.0- and 13.9-fold respectively when incubated with mouse serum. Compared to native GLP-1, both glycosylated GLP-1 analogues modified at Asn34 by asialyl and sialyl N-glycan demonstrated lower maximum blood glucose levels, as well as more rapid and more persistent glucose-stabilizing capability in type 2 diabetic db/db mice. Our results indicated that the selection of an appropriate position (to avoid hindering the peptide-receptor binding) is crucial for N-glycan modification and its sialylation to improve the therapeutic properties of the modified peptides. The information learned would facilitate future design of therapeutic glycopeptides/glycoproteins with N-glycan to achieve enhanced pharmacological properties.
- 12 September 2022
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 8 (10) , 2198-2206
Chemoenzymatic Synthesis of SARS-CoV-2 Homogeneous O-Linked Glycopeptides for Exploring Their Inhibition Functions
Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2. But how the O-glycosylation affects their inhibition abilities has not been intensively explored. Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies. Compared with the unglycosylated peptide, the binding of sT-P320-334 to hACE2 was enhanced to 133% and the inhibition capacity against RBD-hACE2 binding of sTn- and sT-P320-334 was significantly increased up to 150-410%. Thus, our results suggest the sialic acid residue on the terminal of short O-glycan structures might strengthen the inhibition capacities of these peptide-based inhibitors, which might provide novel optimization directions for the inhibitor design.
- 12 September 2022
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 8 (10) , 2198-2206
Chemoenzymatic Synthesis of SARS-CoV-2 Homogeneous O-Linked Glycopeptides for Exploring Their Inhibition Functions
Harnessing highly conserved peptides derived from the receptor binding domain (RBD) of spike (S) protein to construct peptide-based inhibitors is one of the most effective strategies to fight against the ever-mutating coronavirus SARS-CoV-2. But how the O-glycosylation affects their inhibition abilities has not been intensively explored. Herein, an intrinsic O-glycosylated peptide P320-334 derived from RBD was screened and homogeneous O-linked glycopeptides containing Tn (GalNAcα1-O-Ser/Thr), T (Galβ1-3GalNAcα1-O-Ser/Thr), sialyl-Tn (sTn, Siaα2-6GalNAcα1-O-Ser/Thr), and sialyl-T (sT, Siaα2-3Galβ1-3GalNAcα1-O-Ser/Thr) structures were first synthesized via chemoenzymatic strategies. Compared with the unglycosylated peptide, the binding of sT-P320-334 to hACE2 was enhanced to 133% and the inhibition capacity against RBD-hACE2 binding of sTn- and sT-P320-334 was significantly increased up to 150-410%. Thus, our results suggest the sialic acid residue on the terminal of short O-glycan structures might strengthen the inhibition capacities of these peptide-based inhibitors, which might provide novel optimization directions for the inhibitor design.
- 10 October 2017
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 15 (42) , 8946-8951
Decoding glycan protein interactions by a new class of asymmetric N-glycans
N-Glycans are normally involved in crucial physiological and disease processes by interactions with glycan-binding proteins. So far structurally defined N-glycans have been good candidates for glycan binding study. Herein, a class of homogeneous asymmetric N-glycans was synthesized by coupling glycan-oxazoline and N-glycans using EndoM N175Q catalyzed quick glycan extension. Branch-biased binding and spacial inhibition caused by the bulky group on the other branch of N-glycan were observed in glycan protein interactions involving lectins and these glycans by glycan microarray study. These new compounds are valuable for functional glycomic studies to better understand new functions of glycans and glycan-binding proteins.
- 10 October 2017
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 15 (42) , 8946-8951
Decoding glycan protein interactions by a new class of asymmetric N-glycans
N-Glycans are normally involved in crucial physiological and disease processes by interactions with glycan-binding proteins. So far structurally defined N-glycans have been good candidates for glycan binding study. Herein, a class of homogeneous asymmetric N-glycans was synthesized by coupling glycan-oxazoline and N-glycans using EndoM N175Q catalyzed quick glycan extension. Branch-biased binding and spacial inhibition caused by the bulky group on the other branch of N-glycan were observed in glycan protein interactions involving lectins and these glycans by glycan microarray study. These new compounds are valuable for functional glycomic studies to better understand new functions of glycans and glycan-binding proteins.
- 14 September 2017
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 53 (80) , 11012-11015
H. pylori α1–3/4-fucosyltransferase (Hp3/4FT)-catalyzed one-pot multienzyme (OPME) synthesis of Lewis antigens and human milk fucosides
Helicobacter pylori α1–3/4-fucosyltransferase (Hp3/4FT) was expressed in Escherichia coli at a level of 30 mg L−1 culture and used as a diverse catalyst in a one-pot multienzyme (OPME) system for high-yield production of L-fucose-containing carbohydrates including Lewis antigens such as Lewis a, b, and x, O-sulfated Lewis x, and sialyl Lewis x and human milk fucosides such as 3-fucosyllactose (3-FL), lacto-N-fucopentaose (LNFP) III, and lacto-N-difuco-hexaose (LNDFH) II and III. Noticeably, while difucosylation of tetrasaccharides was readily achieved using an excess amount of donor, the synthesis of LNFP III was achieved by Hp3/4FT-catalyzed selective fucosylation of the N-acetyllactosamine (LacNAc) component in lacto-N-neotetraose (LNnT).
- 14 September 2017
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 53 (80) , 11012-11015
H. pylori α1–3/4-fucosyltransferase (Hp3/4FT)-catalyzed one-pot multienzyme (OPME) synthesis of Lewis antigens and human milk fucosides
Helicobacter pylori α1–3/4-fucosyltransferase (Hp3/4FT) was expressed in Escherichia coli at a level of 30 mg L−1 culture and used as a diverse catalyst in a one-pot multienzyme (OPME) system for high-yield production of L-fucose-containing carbohydrates including Lewis antigens such as Lewis a, b, and x, O-sulfated Lewis x, and sialyl Lewis x and human milk fucosides such as 3-fucosyllactose (3-FL), lacto-N-fucopentaose (LNFP) III, and lacto-N-difuco-hexaose (LNDFH) II and III. Noticeably, while difucosylation of tetrasaccharides was readily achieved using an excess amount of donor, the synthesis of LNFP III was achieved by Hp3/4FT-catalyzed selective fucosylation of the N-acetyllactosamine (LacNAc) component in lacto-N-neotetraose (LNnT).
- 1 September 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (18) , 4285-4287
Cation exchange assisted binding-elution strategy for enzymatic synthesis of human milk oligosaccharides (HMOs)
- 1 September 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (18) , 4285-4287
Cation exchange assisted binding-elution strategy for enzymatic synthesis of human milk oligosaccharides (HMOs)
- 17 July 2017
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 53 (65) , 9075-9077
A novel enzymatic method for synthesis of glycopeptides carrying natural eukaryotic N-glycans
A novel enzymatic approach was developed for facile production of glycopeptides carrying natural eukaryotic N-glycans. In this approach, peptides can be GlcNAcylated at one or two natural N-glycosylation sites via two-step enzymatic reactions catalyzed by an evolved N-glycosyltransferase (ApNGTQ469A) and a glucosamine N-acetyltransferase (GlmA), respectively. The resulting GlcNAc-peptides were further modified by an endo-β-N-acetylglucosaminidase M mutant (EndoMN175Q) to generate glycopeptides. In three steps of enzymatic catalysis, glycopeptides carrying complex-type N-glycans can be efficiently synthesized.
- 17 July 2017
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 53 (65) , 9075-9077
A novel enzymatic method for synthesis of glycopeptides carrying natural eukaryotic N-glycans
A novel enzymatic approach was developed for facile production of glycopeptides carrying natural eukaryotic N-glycans. In this approach, peptides can be GlcNAcylated at one or two natural N-glycosylation sites via two-step enzymatic reactions catalyzed by an evolved N-glycosyltransferase (ApNGTQ469A) and a glucosamine N-acetyltransferase (GlmA), respectively. The resulting GlcNAc-peptides were further modified by an endo-β-N-acetylglucosaminidase M mutant (EndoMN175Q) to generate glycopeptides. In three steps of enzymatic catalysis, glycopeptides carrying complex-type N-glycans can be efficiently synthesized.
- Open Access
- 1 May 2017
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 292 (21) , 8856-8863
Production of homogeneous glycoprotein with multisite modifications by an engineered N-glycosyltransferase mutant
- 1 May 2017
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 292 (21) , 8856-8863
Open AccessProduction of homogeneous glycoprotein with multisite modifications by an engineered N-glycosyltransferase mutant
- 11 October 2016
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 14 (47) , 11106-11116
Identification of the binding roles of terminal and internal glycan epitopes using enzymatically synthesized N-glycans containing tandem epitopes
Glycans play diverse roles in a wide range of biological processes. Research on glycan-binding events is essential for learning their biological and pathological functions. However, the functions of terminal and internal glycan epitopes exhibited during binding with glycan-binding proteins (GBPs) and/or viruses need to be further identified. Therefore, a focused library of 36 biantennary asparagine (Asn)-linked glycans with some presenting tandem glycan epitopes was synthesized via a combined Core Isolation/Enzymatic Extension (CIEE) and one-pot multienzyme (OPME) synthetic strategy. These N-glycans include those containing a terminal sialyl N-acetyllactosamine (LacNAc), sialyl Lewis x (sLex) and Siaα2–8-Siaα2–3/6-R structures with N-acetylneuraminic acid (Neu5Ac) or N-glycolylneuraminic acid (Neu5Gc) sialic acid form, LacNAc, Lewis x (Lex), α-Gal, and Galα1–3-Lex; and tandem epitopes including α-Gal, Lex, Galα1–3-Lex, LacNAc, and sialyl LacNAc, presented with an internal sialyl LacNAc or 1–2 repeats of an internal LacNAc or Lex component. They were synthesized in milligram-scale, purified to over 98% purity, and used to prepare a glycan microarray. Binding studies using selected plant lectins, antibodies, and viruses demonstrated, for the first time, that when interpreting the binding between glycans and GBPs/viruses, not only the structure of the terminal glycan epitopes, but also the internal epitopes and/or modifications of terminal epitopes needs to be taken into account.
- 11 October 2016
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 14 (47) , 11106-11116
Identification of the binding roles of terminal and internal glycan epitopes using enzymatically synthesized N-glycans containing tandem epitopes
Glycans play diverse roles in a wide range of biological processes. Research on glycan-binding events is essential for learning their biological and pathological functions. However, the functions of terminal and internal glycan epitopes exhibited during binding with glycan-binding proteins (GBPs) and/or viruses need to be further identified. Therefore, a focused library of 36 biantennary asparagine (Asn)-linked glycans with some presenting tandem glycan epitopes was synthesized via a combined Core Isolation/Enzymatic Extension (CIEE) and one-pot multienzyme (OPME) synthetic strategy. These N-glycans include those containing a terminal sialyl N-acetyllactosamine (LacNAc), sialyl Lewis x (sLex) and Siaα2–8-Siaα2–3/6-R structures with N-acetylneuraminic acid (Neu5Ac) or N-glycolylneuraminic acid (Neu5Gc) sialic acid form, LacNAc, Lewis x (Lex), α-Gal, and Galα1–3-Lex; and tandem epitopes including α-Gal, Lex, Galα1–3-Lex, LacNAc, and sialyl LacNAc, presented with an internal sialyl LacNAc or 1–2 repeats of an internal LacNAc or Lex component. They were synthesized in milligram-scale, purified to over 98% purity, and used to prepare a glycan microarray. Binding studies using selected plant lectins, antibodies, and viruses demonstrated, for the first time, that when interpreting the binding between glycans and GBPs/viruses, not only the structure of the terminal glycan epitopes, but also the internal epitopes and/or modifications of terminal epitopes needs to be taken into account.